Status:
COMPLETED
Immune Response Under Immunotherapy in Metastatic NSCLC: Sputum, Blood Samples and Microbioata Study
Lead Sponsor:
University Hospital, Tours
Collaborating Sponsors:
Cedars-Sinai Medical Center
Conditions:
Non-squamous Lung Cancer
Metastatic Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Prospective pathophysiological exploratory monocentric study, focusing on adult patients with non-small cell lung cancer (NSCLC) : non-squamous type without oncogenic addiction, metastatic, treated wi...
Detailed Description
The percentage of patients benefiting from immunotherapy is quite low and their systemic side effects can sometimes be severe. One of the main difficulties is to identify before treatment patients who...
Eligibility Criteria
Inclusion
- Age of 18 years or over
- Diagnosis of metastatic NSCLC (Stage IV) adenocarcinoma only
- Absence of oncogenic addiction (EGFR, ALK, ROS1, RET, MET, BRAF)
- Treatment with ICI anti-PD1 or anti-PDL1 (pembrolizumab or atezolizumab) as 1st line treatment alone or in combination with chemotherapy and/or anti-angiogenic (bevacizumab).
- 1st injection of ICI, whether or not combined with chemotherapy
Exclusion
- Patient under judicial protection
- Pregnant or breastfeeding women
- NSCLC of the epidermal or undifferentiated type
- Opposition to data processing
Key Trial Info
Start Date :
May 3 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2023
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04804137
Start Date
May 3 2021
End Date
July 31 2023
Last Update
January 17 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Ferreira Marion
Los Angeles, California, United States, 90048
2
University hospital
Tours, France, 37000